DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Klinefelter's syndrome — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleKlinefelter's syndrome maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for klinefelter's syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
androgen receptor (AR) — AR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1r,2rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5CJ6 · 2.07 Å · ligand 2-chloro-4-{[(1R,2R)-2-hydroxy-2-methylcyclopentyl]amino}-3-methylbenzonitrile (51Y). Experimental structure, not a prediction.
What the evidence adds up to
Klinefelter syndrome is a chromosomal disorder with no standardised management guidelines; treatment is guided by the timing of diagnosis and the degree of symptoms, according to a 2019 review. The syndrome affects one in 660 men, with key findings of small testes, hypergonadotropic hypogonadism and cognitive impairment. Medical treatment is mainly testosterone replacement therapy to alleviate acute and long-term consequences of hypogonadism and to treat or prevent frequent comorbidity. A 2015 review reports that men with Klinefelter syndrome score significantly below education-matched controls on cognitive tests, with verbal skills showing the largest effects; many need speech therapy, suffer from learning disability, and may benefit from special education. The same review states that few become fathers and fewer live with a partner compared with controls, and that socioeconomic status and educational level are severely affected, with many achieving only shorter education, low income, and early retirement.
A 2023 paper notes that as few as one in four people with Klinefelter syndrome are correctly diagnosed. The syndrome is associated with venous thromboembolism, and the authors argue that improved education and prophylactic measures could prevent some of the health and quality-of-life consequences. A 2001 review of psychiatric disorders in Klinefelter syndrome describes a psychopathological phenotype comprising psychoses, depressive diseases and personality disorders, and notes that a substantial number of patients present with mild to moderate mental retardation. The 2015 review adds that new studies are elucidating aspects of cognitive functioning and suggest neuropsychological treatment may be of value.
What is still missing is a standardised set of management guidelines, as noted in 2019. The 2015 review indicates that the need for psychological and cognitive treatment is evident in many cases, but no specific drug repurposing trials for the cognitive or psychiatric features are reported in these abstracts. The 2023 paper highlights that diagnosis rates remain low, which limits the ability to study or intervene in the associated thrombotic risk. No trial data on any drug for the core features of Klinefelter syndrome beyond testosterone replacement are described.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
F1000Research · 2019 · 56 citations · open access
Recent advances in managing and understanding Klinefelter syndrome
AbstractKlinefelter syndrome can present as a wide spectrum of clinical manifestations at various stages in life, making it a chromosomal disorder with no standardized set of guidelines for appropriate management. Understanding the genetic and hormonal causes of this syndrome can allow physicians to treat each patient on a more individualized basis. The timing of diagnosis and degree of symptoms can guide management. This report will provide an updated review of the clinical presentation at various stages in life and the implications for management.
Current Opinion in Endocrinology Diabetes and Obesity · 2015 · 46 citations
Neuropsychology and socioeconomic aspects of Klinefelter syndrome
AbstractPURPOSE OF REVIEW: To summarize recent important studies on neuropsychology and epidemiology of Klinefelter syndrome. PubMed was searched for 'Klinefelter', 'Klinefelter's' and 'XXY' in titles and abstracts. Relevant studies were obtained and reviewed, as well as other articles selected by the authors. RECENT FINDINGS: Klinefelter syndrome is the most common sex-chromosome disorder in humans, affecting one in 660 men. The key findings in Klinefelter syndrome are small testes, hypergonadotropic hypogonadism and cognitive impairment. Klinefelter syndrome scores significantly below education matched controls on a range of cognitive tests with verbal skills displaying the largest effects. Boys with Klinefelter syndrome are often in the need of speech therapy and many suffer from learning disability and may benefit from special education. New studies are elucidating aspects of cognitive functioning and suggesting that neuropsychological treatment may be of value. The socioeconomic status and educational level of Klinefelter syndrome is severely affected with many struggling to achieve any or only shorter education, resulting in low-income levels and early retirement. In addition, few become fathers and fewer live with a partner compared with controls. Medical treatment is mainly testosterone replacement therapy in order to alleviate acute and long-term consequences of hypogonadism, as well as, treating or preventing the frequent comorbidity. SUMMARY: The neurocognitive phenotype of Klinefelter syndrome is being unraveled and the need for psychological and cognitive treatment in many cases is evident. The neurocognitive deficits no doubt influence the socioeconomic status of many Klinefelter syndrome patients, which is clearly inferior to age-matched controls.
Trends in Urology & Men s Health · 2023 · 2 citations · open access
Venous thromboembolism in Klinefelter syndrome: a clot in the knowledge?
AbstractAs few as 1 in 4 people with Klinefelter syndrome are correctly diagnosed. The disease is primarily characterised by hypogonadism and infertility, but a number of other conditions are associated with the syndrome, notably venous thromboembolism. The syndrome therefore has significant implications for health outcomes and quality of life that could be prevented with improved education and prophylactic measures.
Klinefelter syndroom en psychiatrische stoornissen: Twee gevalsbeschrijvingen en een literatuuroverzicht
AbstractKlinefelter syndrome is a genetically determined disorder characterized by an additional X-chromosome. Apart from the phenotypical features, the literature about this disorder mentiones a psychopathological phenotype comprising mainly psychoses, depressive diseases and personality disorders. A substantial number of patients presents with mild to moderate mental retardation. In this paper, two case reports are described and their psychopathology is compared with the data from the existing literature.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
